- Pizotifen Malate
-
- $0.10 / 1KG
-
2025-12-24
- CAS:5189-11-7
- Min. Order: 1KG
- Purity: 99.0%
- Supply Ability: 1000 tons
- Pizotifen Malate
-
- $29.00 / 50mg
-
2025-12-22
- CAS:5189-11-7
- Min. Order:
- Purity: 99.96%
- Supply Ability: 10g
- Pizotifen Malate
-
- $29.00 / 50mg
-
2025-12-16
- CAS:5189-11-7
- Min. Order:
- Purity: 99.96%
- Supply Ability: 10g
|
| | Pizotifen Malate Basic information |
| Product Name: | Pizotifen Malate | | Synonyms: | sandomygranmalate;sanomtgran;4-(9,10-DIHYDRO-1-THIA-BENZO[F]AZULEN-4-YLIDENE)-1-METHYL-PIPERIDINE, COMPOUND WITH 2-HYDROXY-SUCCINIC ACID;PIZOTYLINE MALATE;PIZOTIFEN MALATE;9,10-Dihydro-4-(1-methylpiperidin-4-ylidene)-4H-benzo[4,5]cyclohepta[1,2-b]thiophene malate (1:1);malic acid, compound with 4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine (1:1);Einecs 225-970-4 | | CAS: | 5189-11-7 | | MF: | C23H27NO5S | | MW: | 429.53 | | EINECS: | 225-970-4 | | Product Categories: | Active Pharmaceutical Ingredients;Sandomigran, pizotyline;API | | Mol File: | 5189-11-7.mol |  |
| | Pizotifen Malate Chemical Properties |
| Melting point | 185-186° (dec) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | Aqueous Acid (Slightly, Heated), DMSO (Slightly), Methanol (Slightly) | | form | Solid | | color | White to Off-White | | Stability: | Hygroscopic |
| | Pizotifen Malate Usage And Synthesis |
| Uses | Antimigraine | | Uses | Pizotifen, C19H21NS· C4H6O5, is piperidine derivatives. Though antihistamines, it is mainly used because of their antiserotonergic properties. | | Uses | Pizotifen Malate is an anti migraine drug. | | Definition | ChEBI: A malate salt resulting from the reaction of equimolar amounts of pizotifen and malic acid. A sedating antihistamine with strong serotonin antagonist and weak antimuscarinic activity, it is used for the treatment of migraine and the prevention of headache
ttacks during cluster periods. | | in vivo | The weights of the fetuses are significantly reduced by all administered doses of Pipethiadene and Pizotifen malate (BC-105 malate) ; the weights of the placentas are significantly reduced after 0.6 and 1.2 mg/kg Pipethiadene and only after the middle dose of Pizotifen malate. The means of the implantations, live, dead fetuses, resorptions and the occurrence of external, skeletal and visceral anomalies do not differ from the control group. The number of chromosome aberrations in the bone marrow cells of treated mice does not differ significantly from the negative control group. The micronucleus test reveals no elevation in the frequency of micronuclei as compared to the control group. After the two higher doses of both Pipethiadene and Pizotifen maleate, the mitotic indices are lower than in the control group[3]. | | IC 50 | 5-HT2A Receptor; 5-HT1C Receptor |
| | Pizotifen Malate Preparation Products And Raw materials |
|